Table 1 Basic characteristics of Cohort270 and the SCAN-B cohort.
Cohort | Cohort270 | SCAN-B | ||
|---|---|---|---|---|
Age at diagnosis (years) | Median = 62 (29–92) | Median = 64 (24–96) | ||
Node status | Positive | 113 (43%) | Positive | 1167 (37%) |
Negative | 152 (57%) | Negative | 2011 (63%) | |
Missing | 5 | Missing | 93 | |
Tumor size | ≤20 mm | 135 (50%) | ≤20 mm | 2119 (65%) |
>20 mm | 134 (50%) | >20 mm | 1118 (35%) | |
Missing | 1 | Missing | 34 | |
Estrogen receptor | Positive (≥10%) | 233 (86%) | Positive (≥10%) | 2831 (92%) |
Negative (<10%) | 37 (14%) | Negative (<10%) | 240 (8%) | |
Missing | 200 | |||
Progesterone receptor | Positive (≥10%) | 205 (76%) | Positive (≥10%) | 2552 (87%) |
Negative (<10%) | 65 (24%) | Negative (<10%) | 382 (13%) | |
Missing | 333 | |||
HER2 amplification | Not amplified | 231 (86%) | Not amplified | 2729 (87%) |
Amplified | 39 (14%) | Amplified | 420 (13%) | |
Missing | 122 | |||
Grade | Grade = 1 | 33 (12%) | Grade = 1 | 495 (15%) |
Grade = 2 | 123 (46%) | Grade = 2 | 1532 (48%) | |
Grade = 3 | 114 (42%) | Grade = 3 | 1183 (37%) | |
Missing | 61 | |||
Endocrine therapy | Missing | Yes | 2536 (78%) | |
No | 714 (22%) | |||
Missing | 21 | |||
Chemotherapy | Missing | Yes | 1299 (40%) | |
No | 1952 (60%) | |||
Missing | 20 | |||
Recurrences | No recurrence | 246 | Missing | |
Recurrence | 19 | |||
Missing | 5 | |||
Follow-up time (days) | Median = 1840 (91–2533) | |||
Vital status | Alive | 222 | Alive | 2935 |
Deceased | 48 | Deceased | 336 | |
Follow-up time (days) | Median = 2332 (1031–2810) | Median = 1642 (59–2474) | ||
Year of diagnosis | 2007–2010 | 2010–2015 | ||
Hospital | Malmö | All Southern Swedish hospitals | ||
